在芬兰,转移性NSCLC患者在现实世界中
Heikki Ekroos1, Olivia Hölsä2, Anna Kreutzman3
1HUS, Helsinki University Hospital, Helsinki, Finland.
Acta oncologica (Stockholm, Sweden)
|December 16, 2025
概括
转移性非小细胞肺癌 (mNSCLC) 的治疗正在发展,免疫瘤学 (IO) 和氨酸激酶抑制剂 (TKI) 与单独化疗相比显示出更好的生存结果.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 公共卫生 公共卫生
背景情况:
- 转移性非小细胞肺癌 (mNSCLC) 管理已经取得了重大进展.
- 了解真实世界的患者特征,治疗模式和结果对于优化护理至关重要.
研究的目的:
- 研究mNSCLC患者的特征,治疗模式和结果.
- 根据组织学和PD-L1状态分析子组.
- 评估不断发展的疗法对患者存活率的影响.
主要方法:
- 2019年1月至2023年8月期间,赫尔辛基大学医院 (HUS) 电子健康记录的回顾性分析.
- 包括646名接受全身治疗的mNSCLC患者.
- 对患者人口统计,治疗方法和整体存活率的分析.
主要成果:
- 患者的中位年龄为70岁;腺癌是最常见的组织学 (68%).
- 治疗模式转向增加免疫瘤学 (IO) 和氨酸激酶抑制剂 (TKI) 的使用.
- 平均整体存活时间有显著差异:单独使用化疗 (8个月),IO治疗 (12个月),IO + 化疗 (14个月) 和TKI (24个月).
结论:
- 现实世界的数据表明mNSCLC的治疗模式正在演变,IO和TKI利用率显著增加.
- 仅仅化学疗法正在下降,需要进一步监测.
- 评估当前的结果对于资源分配和改善NSCLC患者预后至关重要.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...